• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advanced Functional Materials >Cancer Cell Membrane-Biomimetic Oxygen Nanocarrier for Breaking Hypoxia-Induced Chemoresistance
【24h】

Cancer Cell Membrane-Biomimetic Oxygen Nanocarrier for Breaking Hypoxia-Induced Chemoresistance

机译：癌细胞膜仿生氧纳米载体打破缺氧诱导的化学抗性

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The inadequate oxygen supply in solid tumor causes hypoxia, which leads to drug resistance and poor chemotherapy outcomes. To solve this problem, a cancer cell membrane camouflaged nanocarrier is developed with a polymeric core encapsulating hemoglobin (Hb) and doxorubicin (DOX) for efficient chemotherapy. The designed nanoparticles (DHCNPs) retain the cancer cell adhesion molecules on the surface of nanoparticles for homologous targeting and possess theoxygen-carrying capacity of Hb for O-2-interfered chemotherapy. The results show that DHCNPs not only achieve higher tumor specificity and lower toxicity by homologous targeting but also significantly reduce the exocytosis of DOX via suppressing the expressions of hypoxia-inducible factor-1 alpha, multidrug resistance gene 1, and P-glycoprotein, thus resulting in safe and high-efficient chemotherapy. This work presents a new paradigm for targeted oxygen interference therapy by conquering hypoxia-involved therapeutic resistance and achieves effective treatment of solid tumors.
机译：实体瘤中的氧气供应不足会导致缺氧，从而导致耐药性和较差的化疗结果。为了解决这个问题，开发了一种带有癌细胞核膜的纳米载体，该载体具有包裹血红蛋白（Hb）和阿霉素（DOX）的聚合物核，可进行有效的化学疗法。设计的纳米粒子（DHCNPs）将癌细胞粘附分子保留在纳米粒子的表面上用于同源靶向，并具有Hb的携氧能力以进行O-2-干扰化学疗法。结果表明，DHCNPs不仅可以通过同源靶向实现更高的肿瘤特异性和更低的毒性，而且还可以通过抑制缺氧诱导因子-1α，多药耐药基因1和P-糖蛋白的表达来显着减少DOX的胞吐作用，从而导致在安全高效的化疗中。这项工作通过克服涉及缺氧的治疗耐药性，提出了靶向氧干预治疗的新范例，并实现了对实体瘤的有效治疗。

著录项

  • 来源
    《Advanced Functional Materials》 |2017年第38期|1703197.1-1703197.7|共7页
  • 作者

    Tian Hao; Luo Zhenyu; Liu Lanlan; Zheng Mingbin; Chen Ze; Ma Aiqing; Liang Ruijing; Han Zhiqun; Lu Chengyu; Cai Lintao;

  • 作者单位

    Chinese Acad Sci, Guangdong Key Lab Nanomed, CAS Key Lab Hlth Informat, Inst Biomed & Biotechnol,SIAT, Shenzhen 518055, Peoples R China|Guangdong Med Univ, Dept Pharm, Dongguan 523808, Peoples R China;

    Chinese Acad Sci, Guangdong Key Lab Nanomed, CAS Key Lab Hlth Informat, Inst Biomed & Biotechnol,SIAT, Shenzhen 518055, Peoples R China|Univ Chinese Acad Sci, Beijing 100049, Peoples R China;

    Chinese Acad Sci, Guangdong Key Lab Nanomed, CAS Key Lab Hlth Informat, Inst Biomed & Biotechnol,SIAT, Shenzhen 518055, Peoples R China|Univ Chinese Acad Sci, Beijing 100049, Peoples R China;

    Chinese Acad Sci, Guangdong Key Lab Nanomed, CAS Key Lab Hlth Informat, Inst Biomed & Biotechnol,SIAT, Shenzhen 518055, Peoples R China|Guangdong Med Univ, Dept Pharm, Dongguan 523808, Peoples R China;

    Chinese Acad Sci, Guangdong Key Lab Nanomed, CAS Key Lab Hlth Informat, Inst Biomed & Biotechnol,SIAT, Shenzhen 518055, Peoples R China;

    Chinese Acad Sci, Guangdong Key Lab Nanomed, CAS Key Lab Hlth Informat, Inst Biomed & Biotechnol,SIAT, Shenzhen 518055, Peoples R China|Guangdong Med Univ, Dept Pharm, Dongguan 523808, Peoples R China;

    Chinese Acad Sci, Guangdong Key Lab Nanomed, CAS Key Lab Hlth Informat, Inst Biomed & Biotechnol,SIAT, Shenzhen 518055, Peoples R China;

    Chinese Acad Sci, Guangdong Key Lab Nanomed, CAS Key Lab Hlth Informat, Inst Biomed & Biotechnol,SIAT, Shenzhen 518055, Peoples R China;

    Guangdong Med Univ, Dept Pharm, Dongguan 523808, Peoples R China;

    Chinese Acad Sci, Guangdong Key Lab Nanomed, CAS Key Lab Hlth Informat, Inst Biomed & Biotechnol,SIAT, Shenzhen 518055, Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    biomimetic nanoparticles; chemotherapy; homologous targeting; oxygen nanocarriers; tumor hypoxia;

    机译：仿生纳米粒子;化学疗法;同源靶向;氧纳米载体;肿瘤缺氧;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号